Pharmaceuticals New Zealand

New Zealand Microbiome Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

New Zealand Microbiome Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Product, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

New Zealand · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $8.8 Mn Placeholder estimate
Estimate 2025 $11.5 Mn 1.1% of the global market
Projected 2034 $119.8 Mn 945.9% Adds $108.4 Mn over 9 forecast years
CAGR 2025–2034 29.8% Faster than 96% of 160 Pharmaceuticals markets here
Key players 5
  • New Zealand is 1.13% of the global market.
  • In APAC, the largest is China at $78.1 Mn.
  • Fastest growing: India at 33.1% a year.
  • New Zealand ranks 4th of 10 by size in APAC.

Market size projection

New Zealand

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$108.4 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Microbiome Therapeutics Market market size by year, New Zealand
YearMarket sizeChange that yearSince 2025
2024 (estimate) $8.8 Mn — —
2025 (base) $11.5 Mn +$2.6 Mn —
2026 (forecast) $14.9 Mn +$3.4 Mn +29.8%
2027 (forecast) $19.3 Mn +$4.4 Mn +68.5%
2028 (forecast) $25.1 Mn +$5.8 Mn +118.7%
2029 (forecast) $32.5 Mn +$7.5 Mn +183.9%
2030 (forecast) $42.2 Mn +$9.7 Mn +268.4%
2031 (forecast) $54.8 Mn +$12.6 Mn +378.2%
2032 (forecast) $71.1 Mn +$16.3 Mn +520.8%
2033 (forecast) $92.3 Mn +$21.2 Mn +705.7%
2034 (forecast) $119.8 Mn +$27.5 Mn +945.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

New Zealand Microbiome Therapeutics Market Analysis at a glance
Market size, 2025$11.5 Mn placeholder estimate
Forecast, 2034$119.8 Mn placeholder estimate
Growth (CAGR), 2025–203429.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, indication and end user (see all)
Key playersSeres Therapeutics, Ferring Pharmaceuticals, Vedanta Biosciences, MaaT Pharma, Nestle (see all)
Regulator in New ZealandMedsafeSource: Medsafe. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The New Zealand Microbiome Therapeutics Market Analysis Executive Summary

Microbiome therapeutics use live bacteria or their products as medicines, for infections, bowel disease and other conditions.

Key segments of the microbiome Therapeutics market include product (Fecal Microbiota Products, Live Biotherapeutics and Microbiome Modulators) and indication (C. difficile, IBD and Oncology).

Bar chart: New Zealand Microbiome Therapeutics market size, 2024–2034, placeholder estimates. $8.8 Mn in 2024, $11.5 Mn in 2025 and $119.8 Mn in 2034, 29.8% CAGR.
New Zealand Microbiome Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

New Zealand Microbiome Therapeutics Market Dynamics

Market Growth Drivers

Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the microbiome Therapeutics market.

Opportunity

Microbiome-based treatments, earlier testing and digital gut-health programmes give the microbiome Therapeutics market room to grow.

Market Restraints

Late diagnosis, stigma, limited specialist access and high prices of new medicines hold back the microbiome Therapeutics market.

Competitive Landscape for Microbiome Therapeutics Market in New Zealand

The microbiome Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Microbiome Therapeutics Market in New Zealand

Microbiome Therapeutics in New Zealand: rules and payment

Medsafe, part of the Ministry of Health, approves medicines before they can be sold.⁠[1] Pharmac decides which medicines and medical devices the public health system pays for.⁠[2]

[1] Medsafe. Checked 14 Nov 2026.

[2] Pharmac. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for microbiome Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in New Zealand.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Microbiome Therapeutics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Microbiome Therapeutics in context

New Zealand compared

  • Health spending per person: 5,022 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 17 countries we cover in APAC.[1]
  • Doctors: 3.61 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 17.6% of people (2025). World: 10.4% of people (2025). 5th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Microbiome Therapeutics market in New Zealand?
Placeholder estimate: about $11.5 Mn in 2025, rising to about $119.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Microbiome Therapeutics market in New Zealand growing?
Placeholder estimate: about 29.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Microbiome Therapeutics market report cover?
The report splits the market by product (Fecal Microbiota Products, Live Biotherapeutics, Microbiome Modulators), indication (C. difficile, IBD, Oncology, Metabolic Disease) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Microbiome Therapeutics market?
Key players include Seres Therapeutics, Ferring Pharmaceuticals, Vedanta Biosciences, MaaT Pharma and Nestle.
What is driving the Microbiome Therapeutics market?
Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the microbiome Therapeutics market.
Who regulates Microbiome Therapeutics in New Zealand?
Medsafe, part of the Ministry of Health, approves medicines before they can be sold. Source: Medsafe. Checked 14 Nov 2026.
How is healthcare paid for in New Zealand?
Pharmac decides which medicines and medical devices the public health system pays for. Source: Pharmac. Checked 14 Nov 2026.
How much research is published on Microbiome Therapeutics?
PubMed lists 151 papers on Microbiome Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in New Zealand

See all

Related on gut health and biologics and biosimilars

See the topic